5-Amino-1MQ Dosage Guide: Protocols, Calculator & Safety

The defensible beginner protocol for 5-amino-1MQ is to not use it, and to instead implement the validated interventions that produce the outcomes 5-amino-1MQ is supposed to produce. For body composition and metabolic health, the evidence base for resistance training (3-5 sessions per week with progressive overload), adequate protein (1.6-2.2 g/kg/day with emphasis on leucine-rich sources), caloric discipline calibrated to goals, 7-9 hours of sleep, and — when clinically indicated — FDA-approved medications (Semaglutide, Tirzepatide, metformin for insulin resistance) is orders of magnitude more robust than the evidence for any investigational NNMT inhibitor. For sarcopenia prevention or mitigation in older adults, resistance training remains the most effective intervention ever studied, with meta-analytic evidence for increases in muscle mass, strength, and functional capacity across age groups including the very elderly. Adequate protein, creatine monohydrate (5 g daily), and vitamin D sufficiency are the supplement interventions with the best evidence in sarcopenia. 5-amino-1MQ belongs in the conversation about experimental sarcopenia interventions, but experimental is the operative word. If you proceed with 5-amino-1MQ despite the above, a starting protocol is 50-100 mg orally once daily, taken in the morning with or without food, for 4-8 weeks. This dose range is chosen based on rodent efficacy data scaled to human body weight using conventional allometric scaling, with the acknowledgment that allometric scaling for novel research chemicals is not validated and actual human dose-response is unknown. Administration is typically as a capsule (research-chemical vendors commonly supply either capsules or raw powder); oral bioavailability in humans is unknown but is presumed reasonable given the compound's structural class and rodent pharmacokinetic data. Food effects on absorption are not characterized but intuitively minimal for a small water-soluble compound. Morning dosing is common to avoid any theoretical sleep effects from altered NAD+ or methyl metabolism, though no evidence supports morning over evening dosing specifically. Beginners should use 5-amino-1MQ alone without stacking — the principle of single-agent experimentation for attribution applies strongly here because the expected effects are subjective or require biomarker measurement to detect, and stacking obscures the ability to attribute any effects you notice to 5-amino-1MQ specifically. Endpoints to monitor during a beginner cycle include: body weight and body composition (ideally DEXA at start and end of cycle, though weekly scale weight and monthly circumference measurements are acceptable); strength metrics (top sets on main lifts, grip strength if a dynamometer is available); subjective energy and recovery; comprehensive metabolic panel before and after the cycle; fasting glucose and HbA1c if metabolic health is the focus; lipid panel for cardiometabolic monitoring; and homocysteine to detect methyl balance issues. Expectations should be calibrated: a beginner 4-8 week cycle at 50-100 mg daily is unlikely to produce dramatic body composition change unless combined with training and caloric discipline, and the effect of the compound in isolation may not be subjectively obvious. This is consistent with a compound working at the mechanism level it is intended to work at rather than being a stimulant or an anabolic agent. Persistence without subjective effects does not establish absence of effect, and presence of subjective effects does not establish that the compound is the cause. The beginner protocol is also where expectations about stopping should be set: the plan is 4-8 weeks of dosing followed by a washout of at least equal duration, and this cadence should be held regardless of whether perceived benefits are accumulating or not. Open-ended continuous dosing of an unvalidated research chemical is not a reasonable approach even for users who feel they are benefiting, because cumulative exposure is the axis along which long-term safety risks would manifest. Labs before and after each cycle provide the objective data needed to evaluate whether the experimentation is producing measurable changes, and absence of beneficial change despite subjective improvement is a reason to reconsider continued use.

Intermediate users of 5-amino-1MQ have completed one or more beginner cycles without adverse effects, have baseline and follow-up labs that have remained within normal limits, and are considering higher doses, longer cycles, or combination with other interventions. A typical intermediate protocol involves 100-150 mg orally daily for 8-12 weeks, either as a single morning dose or divided twice daily, followed by an equal washout period. The rationale for divided dosing is pharmacokinetic — if the plasma half-life is shorter than 12 hours, divided dosing may maintain more sustained enzyme inhibition through the day, though actual human pharmacokinetics are not published. The counterargument is that divided dosing doubles inconvenience and pill count without documented benefit. Intermediate cycles commonly include limited stacking with complementary interventions. Methyl donor support (trimethylglycine 500-1000 mg daily, methylfolate 400-800 mcg daily, methylcobalamin 500-1000 mcg daily) is a reasonable addition for anyone concerned about methylation homeostasis during prolonged NNMT inhibition. Creatine monohydrate (5 g daily) provides additional muscle support and methyl donor supply through creatine synthesis bypass. NAD+ precursor supplementation (NR 300-500 mg daily or NMN 250-500 mg daily) is mechanistically compatible with NNMT inhibition, though whether this combination outperforms either intervention alone is not established. Creatine, methyl donors, and NAD+ precursors are individually well-tolerated and the combination has no obvious contraindications. Exercise at this stage should be structured and progressive, with resistance training emphasizing compound movements, adequate volume (10-20 sets per major muscle group per week), and periodization. Cardiovascular training 2-3 times per week supports mitochondrial adaptation. The combination of NNMT inhibition with structured exercise is where the mechanistic rationale of 5-amino-1MQ is most coherent — aging muscle has elevated NNMT, and NNMT inhibition may preserve NAD+ to support exercise-induced adaptation. Isolated compound use without training stimulus provides no biological reason to expect muscle improvement. Monitoring at intermediate stages should include: quarterly comprehensive metabolic panel, CBC, liver function tests; lipid panel with ApoB; fasting glucose and HbA1c; homocysteine and B12 for methyl balance; vitamin D; ferritin; thyroid panel. Body composition tracking with DEXA or equivalent at 12-week intervals provides objective data on the effects of the protocol. Strength metrics on primary lifts (back squat, deadlift, bench press, overhead press) tracked weekly or biweekly quantify training response. Grip strength measurements provide a proxy for overall muscle function, particularly relevant in older adults. Sleep quality, resting heart rate, and heart rate variability (via consumer wearables) provide systemic wellness indicators. Any unexplained abnormality on labs or sustained negative trend in performance metrics should prompt cessation and evaluation. Duration at intermediate doses is typically 8-12 weeks on, 4-8 weeks off, with 2-3 cycles per year. Year-long continuous dosing is not supported by data and may mask the ability to detect cumulative effects. The intermediate stage is also where the question of whether to continue the protocol becomes relevant. If multiple cycles have produced measurable benefit on body composition or performance metrics that are sustained during washout periods, the protocol is arguably worth continuing. If cycles produce transient effects that regress during washout, the protocol's value is less clear. If cycles produce no measurable change despite appropriate training and nutrition, continuing to invest in the protocol is probably not justified. These are judgment calls that the user must make based on personal data, but the bias should be toward stopping an unvalidated intervention that is not demonstrably helping rather than continuing indefinitely on faith. Intermediate users should also verify vendor quality. Research-chemical vendors vary in manufacturing practices, purity, and honesty about content. Compounds tested by third-party analytical labs (LC-MS identity, HPLC purity) should be preferred over compounds without independent verification. A vendor that publishes certificates of analysis from reputable testing labs is safer than one that does not. The economic burden of ongoing use is also worth addressing — multi-month supplies at intermediate doses can cost several hundred dollars, and whether the benefit justifies the expense is an individual decision, but the displacement of resources from validated investments (high-quality food, training equipment, medical care) should be considered.

Advanced 5-amino-1MQ protocols involve higher doses, longer cycles, or sophisticated multi-compound stacking in experienced users who have established tolerance and baseline health data through prior cycles. Advanced dosing typically involves 150-300 mg orally daily, sometimes divided, for cycles of 12-24 weeks. There is no clinical evidence that doses above the intermediate range produce better outcomes, and dose-response for NNMT inhibition likely reaches saturation within the intermediate range given the enzyme's fixed capacity in a given tissue. Higher doses primarily increase off-target effects, systemic exposure, and risk of cumulative adverse consequences rather than increasing target effect. Advanced users often stack 5-amino-1MQ within comprehensive longevity protocols that include NAD+ precursors (NR or NMN), methyl donors, creatine, omega-3 fatty acids, vitamin D, magnesium, and potentially multiple research peptides or compounds targeting aging pathways: Epithalon for telomere support, Thymosin Alpha-1 for immune function, BPC-157 and TB-500 for tissue repair, GHK-Cu for skin and connective tissue, CJC-1295/Ipamorelin for GH/IGF-1 support, Methylene Blue for mitochondrial electron transport, Humanin for cytoprotection, rapamycin (if prescribed for off-label longevity use) for mTOR modulation. These comprehensive stacks operate on the assumption that targeting multiple aging pathways simultaneously produces additive or synergistic benefit. The evidence base for any individual element is generally weak for human outcomes, and the evidence base for the combinations is essentially absent. Attribution of effects to any specific intervention becomes impossible, which is a legitimate scientific objection to comprehensive stacking but which does not deter many advanced users who accept that attribution is lost in exchange for perceived coverage. Monitoring at advanced stages must be comprehensive and frequent. Quarterly labs: comprehensive metabolic panel, CBC with differential, liver function tests, lipid panel with ApoB and Lp(a), thyroid panel, fasting glucose and HbA1c, insulin, IGF-1 if GH secretagogues are stacked, homocysteine, vitamin D, B12, folate, ferritin, high-sensitivity CRP, and any condition-specific markers relevant to personal health status. Annual: comprehensive cardiovascular evaluation (coronary calcium score, carotid intima-media thickness, stress testing if indicated); age-appropriate cancer screening (colonoscopy, mammography or prostate testing, skin check); bone density (DEXA); body composition (DEXA); cognitive function if relevant; exercise capacity testing (VO2max). The goal of monitoring at this intensity is to detect subclinical abnormalities early and to adjust the protocol when patterns emerge. Advanced users should also maintain clinical relationships that support the protocol — a physician with expertise in longevity medicine and research peptide pharmacology is substantially more valuable than one without, and finding a clinician with genuine depth in these areas takes effort but is worth the effort. The cost of advanced protocols can be substantial: $5,000-$30,000+ annually depending on compounds stacked, testing frequency, and medical oversight costs. This level of expenditure has opportunity costs — funds not spent on peptides are available for other health investments (high-quality food, training facilities or coaching, therapy, stress management, preventive screening beyond the stack protocol). Users should periodically ask whether the protocol is actually producing measurable benefit commensurate with its cost, or whether inertia and sunk-cost reasoning are maintaining it. Advanced users should also consider the protocol's exit strategy. 5-amino-1MQ is not a drug that requires indefinite dosing for a chronic condition — it is an experimental intervention that should be periodically reassessed. Planned protocol de-escalation, or cessation when baseline health is optimized, is as valid as continuing indefinitely. The discipline of stopping is often harder than starting, but it is part of responsible self-experimentation. The advanced stage is also where bias amplification becomes a serious issue. Users who have invested significant money and hope in a protocol have strong psychological pressure to perceive benefit and to continue despite equivocal data. The most useful mental discipline is to set clear thresholds before starting: if labs do not improve, if performance metrics do not improve, if body composition does not improve, the protocol will be reconsidered rather than continued on faith. Pre-commitment to criteria makes it easier to stop when stopping is warranted.